Thursday, August 6, 2015

Antiva Biosciences Gets $16M

Menlo Park-based Antiva Biosciences, a biopharmaceuticals company developing antiviral drugs to treat Human Papillomavirus infections, said today that it has raised $16M in a Series B funding. The funding came from Canaan Partners and Sofinnova Ventures, along with its original investors. The funding is the company's first institutional round. As part of the funding, Gail Maderis has been named CEO. Maderis was previously CEO of BayBio, and also served at Five Prime Therapeutics and Genzyme. She sits on the boards of NovaBay Pharmaceuticals and Opexa Therapeutics. Photo: Gail Maderis.